Insider Trading Alert - INO, RSG And PRI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 12, 2014, 62 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $8,936,360.00.

Highlighted Stocks Traded by Insiders:

Inovio Pharmaceuticals (INO) - FREE Research Report

Sardesai Niranjan, who is Chief Operating Officer at Inovio Pharmaceuticals, bought 2,550 shares at $8.70 on Aug. 12, 2014. Following this transaction, the Chief Operating Officer owned 28,000 shares meaning that the stake was boosted by 10.02% with the 2,550-share transaction.

The shares most recently traded at $9.28, up $0.58, or 6.25% since the insider transaction. Historical insider transactions for Inovio Pharmaceuticals go as follows:

  • 4-Week # shares bought: 25,000
  • 12-Week # shares bought: 25,000
  • 24-Week # shares bought: 25,000

The average volume for Inovio Pharmaceuticals has been 2.0 million shares per day over the past 30 days. Inovio Pharmaceuticals has a market cap of $539.6 million and is part of the health care sector and drugs industry. Shares are down 25.17% year-to-date as of the close of trading on Tuesday.

Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Currently, there are 5 analysts who rate Inovio Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INO - FREE

TheStreet Quant Ratings rates Inovio Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Inovio Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Republic Services (RSG) - FREE Research Report

Cascade Investment Llc, who is 10% Owner at Republic Services, bought 49,000 shares at $38.52 on Aug. 12, 2014. Following this transaction, the 10% Owner owned 98.4 million shares meaning that the stake was boosted by 0.05% with the 49,000-share transaction.

The shares most recently traded at $38.79, up $0.27, or 0.69% since the insider transaction. Historical insider transactions for Republic Services go as follows:

  • 4-Week # shares bought: 4.9 million
  • 12-Week # shares bought: 8.7 million
  • 24-Week # shares bought: 8.7 million

The average volume for Republic Services has been 1.5 million shares per day over the past 30 days. Republic Services has a market cap of $13.7 billion and is part of the industrial goods sector and materials & construction industry. Shares are up 16.42% year-to-date as of the close of trading on Tuesday.

Republic Services, Inc., together with its subsidiaries, provides non-hazardous solid waste collection, transfer, and recycling and disposal services for commercial, industrial, municipal, and residential customers in the United States and Puerto Rico. The stock currently has a dividend yield of 2.91%. The company has a P/E ratio of 19.3. Currently, there are 5 analysts who rate Republic Services a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RSG - FREE

TheStreet Quant Ratings rates Republic Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Republic Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Primerica (PRI) - FREE Research Report

Williams Donald R., who is Co-Chief Executive Officer at Primerica, sold 30,000 shares at $47.49 on Aug. 12, 2014. Following this transaction, the Co-Chief Executive Officer owned 217,230 shares meaning that the stake was reduced by 12.13% with the 30,000-share transaction.

Addison John A. Jr., who is Co-Chief Executive Officer at Primerica, sold 30,000 shares at $47.61 on Aug. 12, 2014. Following this transaction, the Co-Chief Executive Officer owned 172,534 shares meaning that the stake was reduced by 14.81% with the 30,000-share transaction.

The shares most recently traded at $47.19, down $0.42, or 0.89% since the insider transaction. Historical insider transactions for Primerica go as follows:

  • 4-Week # shares sold: 2,096
  • 12-Week # shares sold: 7,096
  • 24-Week # shares sold: 101,337

The average volume for Primerica has been 227,600 shares per day over the past 30 days. Primerica has a market cap of $2.6 billion and is part of the financial sector and insurance industry. Shares are up 9.76% year-to-date as of the close of trading on Tuesday.

Primerica, Inc., together with its subsidiaries, distributes financial products to middle income households in the United States and Canada. The company operates in three segments: Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. The stock currently has a dividend yield of 1.02%. The company has a P/E ratio of 15.1. Currently, there is 1 analyst who rates Primerica a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRI - FREE

TheStreet Quant Ratings rates Primerica as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Primerica Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Investors Need to Closely Watch Mario Draghi's Speech at Jackson Hole: Market Recon

Investors Need to Closely Watch Mario Draghi's Speech at Jackson Hole: Market Recon

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round